Amgen Inc. (NASDAQ:AMGN) is Brown Lisle Cummings Inc.’s 9th Largest Position

Brown Lisle Cummings Inc. lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,236 shares of the medical research company’s stock after selling 456 shares during the quarter. Amgen accounts for about 1.7% of Brown Lisle Cummings Inc.’s holdings, making the stock its 9th biggest position. Brown Lisle Cummings Inc.’s holdings in Amgen were worth $5,796,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AMF Tjanstepension AB grew its holdings in shares of Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after acquiring an additional 17,387 shares during the period. Czech National Bank boosted its position in Amgen by 7.1% during the third quarter. Czech National Bank now owns 109,459 shares of the medical research company’s stock worth $35,269,000 after purchasing an additional 7,237 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Amgen by 25.7% in the 3rd quarter. GAMMA Investing LLC now owns 10,420 shares of the medical research company’s stock worth $3,357,000 after buying an additional 2,130 shares in the last quarter. WealthBridge Capital Management LLC grew its stake in Amgen by 9.4% in the 3rd quarter. WealthBridge Capital Management LLC now owns 1,025 shares of the medical research company’s stock valued at $330,000 after acquiring an additional 88 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV increased its holdings in Amgen by 44.9% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 8,923 shares of the medical research company’s stock valued at $2,875,000 after acquiring an additional 2,766 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AMGN shares. Bank of America reiterated an “underperform” rating and issued a $256.00 price target on shares of Amgen in a research report on Tuesday, December 10th. Piper Sandler lowered their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Redburn Partners decreased their price objective on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $314.00.

Amgen Stock Up 1.2 %

Shares of Amgen stock opened at $288.87 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $155.28 billion, a price-to-earnings ratio of 36.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a fifty day moving average price of $271.06 and a 200 day moving average price of $304.11.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.30%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.